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Abstract
While pharmacological and behavioral treatments exist for smoking cessation, there are 
currently no best practices for helping adolescents quit smoking. This study aimed to reach consensus 
regarding pharmacist recommendations for adolescent smoking cessation. Using a three-round 
Delphi technique, pharmacists across the USA with experience working with adolescent substance 
use provided quantitative and qualitative feedback on recommendations. Forty pharmacists 
completed Round 1, 37 completed Rounds 2 and 3. In Round 1, 36 (90%) responses included the 
nicotine patch, gum, or lozenge. Ten recommendations were identified in Round 1: nicotine patch, 
nicotine gum, nicotine lozenge, bupropion SR, varenicline, quitline, smoking cessation program, 
counseling, behavioral approaches, and cold turkey. In Round 2, pharmacists were most likely 
to recommend smoking cessation programs (median=7 of 7, Interquartile range [IQR]=1) and 
least likely to recommend varenicline (median=3, IQR=3). In Round 3, consensus to recommend 
was reached on smoking cessation program (83.3% likely or very likely to recommend). Despite 
initially recommending nicotine replacement therapy in Round 1, by Round 3 most pharmacists 
were more likely to recommend behavioral treatments than pharmacological interventions for this 
patient population. Such preferences by pharmacists could influence the accessibility of various 
treatments to adolescent smokers.
ABBREVIATIONS
NRT: Nicotine Replacement Therapy; IQR: Interquartile 
Range
INTRODUCTION
Tobacco use remains the leading preventable cause of disease 
and death worldwide [1]. Despite decades of tobacco prevention 
initiatives, more than 3,800 teens under 18 try smoking each day 
[2]. As their brains are not yet fully developed, adolescents are 
more susceptible to the addictive chemicals within combusted 
cigarettes, and, therefore, more likely to become addicted despite 
sporadic smoking habits [3]. Furthermore, successful quit 
attempts among adolescent smokers are rare, perhaps due to 
lack of best practice guideline for this population [3].
Behavioral strategies have been used in adolescent smoking 
cessation interventions, including cognitive based therapy, 
contingency management, and motivational interviewing, in 
multiple formats such as telephone-based, internet-based, and 
school-based [4]. The most current clinical guideline reported 
some evidence for support for counseling (a broad term which 
covers multiple behavioral approaches) but stated additional 
research is needed in adolescent smoking cessation [3]. 
Medication options include bupropion slow release (SR) 
(i.e. Wellbutrin, Zyban), nicotine gum, nicotine inhaler, nicotine 
lozenge, nicotine nasal spray, nicotine patch, and varenicline 
pills (i.e. Chantix). Each of these treatment options range in 
effectiveness, cost, and insurance coverage and are considered 
first-line medications by the tobacco treatment clinical guidelines, 
which translates to having an established empirical evidence of 
effectiveness [3]. Pharmacological treatments such as the nicotine 
patch, nicotine gum, and nicotine lozenge are available over-
the-counter within the USA but only to individuals ages 18 and 
over. However, such products can be and are obtained by those 
under 18, either from friends, family, or doctor prescription [5,6]. 
Additionally, cessation medications bupropion SR, varenicline, 
nicotine nasal spray, and inhaler are available with prescription. 
There is mixed evidence among pharmacological 
interventions, possibly due to low recruitment and high attrition 
Central
Bringing Excellence in Open Access


King et al. (2017)
Email:  
J Pharmacol Clin Toxicol 5(4): 1080 (2017) 2/6
leading to underpowered studies [7]. Some studies show 
pharmacological treatments may be helpful for adolescents 
looking to quit [8,9], while others report limited success with NRT 
[10,11]. Pharmacological treatments for smoking cessation can 
improve the odds of successfully quitting by 50-70% [3,12,13]. 
NRT is widely used and recommended for adult smoking 
cessation [3], and is considered the most effective strategy for 
quitting when combined with behavioral support [14]. 
Pharmacists, with training in therapeutics and experience 
dispensing medication, offer a unique perspective. While doctors 
often prescribe such medications, pharmacists may have greater 
observational cessation experience through providing education 
alongside medications. Potential for interaction between 
pharmacists and adolescent smokers occurs in several settings, 
including when youth are obtaining other prescriptions or if youth 
are seeking out tobacco or cessation products. Past research with 
adolescents and pharmacists in school settings found positive 
changes in anti-tobacco knowledge [15]. Additionally, trends 
for health education [16-18], vaccinations [19], and smoking 
cessation efforts in pharmacies [20], suggest pharmacists may 
be an untapped resource for adolescent cessation education. 
Furthermore, pharmacist advice or recommendation may play a 
role in adolescents using pharmacological treatments for smoking 
cessation. Given the potential for pharmacist cessation advice, 
this study aimed to address the question: what do pharmacists 
recommend for adolescent smoking cessation?
MATERIALS AND METHODS
Delphi overview
A three-round Delphi technique was used to intensively 
survey a panel of pharmacists experienced with adolescent 
cessation. The technique has been used in medical and health 
services research and is suitable for problems when there is 
insufficient evidence [21]. Devised in the early 1950s to obtain 
feedback from experts, the Delphi technique is a systematic 
approach to garner group consensus while minimizing social bias 
[22]. Delphi study participants never meet face-to-face which 
provides a sense of anonymity and minimizes the influence of 
dominant individuals [21]. 
The Delphi technique combines qualitative and quantitative 
methodologies, beginning with open-ended items within the first 
round and closed-ended survey items within subsequent rounds. 
Successive questionnaires give participants feedback on the 
collective responses of the group and allow subjects to modify 
responses. Throughout, the process builds on the qualitative 
responses of the experts and measures the collective response 
quantitatively [21]. As such, data collected provide a wealth of 
information.
Recruitment
USA State Board of Pharmacy directors were contacted 
between May 18 and June 1, 2015, by email, and asked to 
share with their members a brief overview of the study and the 
screening survey link. Director emails were obtained from the 
National Association Boards of Pharmacy website [23]. Of the 50 
USA states and District of Columbia listed, all but three (Alabama, 
Connecticut, and Tennessee) had email contacts; therefore, the 
directors from 47 states and District of Columbia were contacted 
via up to two emails over a period of two weeks. Of the 47 directors 
contacted, four (Hawaii, Kentucky, Oklahoma, and Wyoming) 
responded saying they would share the information, four 
(Indiana, Texas, Virginia, and Vermont) provided contact lists for 
their members, one (Massachusetts) email link was inactive, 28 
did not respond, and 11 responded saying they were not able to 
forward the information. Of the 11 state directors who would not 
share the information, four (Louisiana, Nebraska, Pennsylvania, 
and South Carolina) offered a contact list for purchase, and four 
(West Virginia, Missouri, New York, and Kansas) said there was 
no list available.
To increase the likelihood of quality responses and ensure 
a diverse expert panel, a brief screening tool requesting 
information on pharmaceutical background and experience 
treating adolescent smokers was administered to all interested 
pharmacists. The screener asked potential panel members about 
their work setting (e.g. retail, hospital, or research), number of 
years practicing, and experience with adolescent smokers. 
The literature varies regarding ideal sample size for a 
Delphi study, with recommendations for between 20 and 100 
participants. Larger samples increase validity, but too large of a 
sample can be time intensive, thus delaying the ability to develop 
and distribute the second and third rounds of the study [22]. 
Based on literature recommendations and feasibility, the goal for 
the current study was to have 30 pharmacists complete Round 
3. Within one week of recruitment, 312 pharmacists completed 
the screening survey. All responses to the screening survey 
were first reviewed for whether pharmacists had previous 
experience working with adolescent smoking cessation. Sixty-
seven (21.5%) pharmacists reported minimal or no experience 
with adolescent cessation, while an additional 8 (2.6%) provided 
unclear responses. From the remaining 237 pharmacists, 50 
pharmacists were invited to participate, selected using stratified 
random sampling based on years of pharmaceutical experience 
and employment sector. Because only those who completed the 
previous round were invited to participate in subsequent rounds, 
50 participants were invited in order to obtain a final sample of 
30 pharmacists. 
Procedure
All surveys were conducted via Qualtrics© online software. 
Participants were provided the following phrase at the start of 
each survey to clarify the target population of adolescents: “The 
following items pertain to teen or adolescent smoking. In this 
context, teen/adolescent refers specifically to an individual under 
the age of 18.” Participants were given two weeks to complete 
each survey, with two weeks between each survey for analyses 
and received a $50 gift card after completing the final round.
Round 1: In Round 1, participants responded to an open-
ended item on recommendations for adolescent smoking 
cessation: “What would you recommend for a teen looking to quit 
smoking?”. All responses were compiled and categorized by two 
independent researchers. Any discrepancies were resolved by a 
third researcher. 
Round 2: In Round 2, participants who completed Round 1 
were asked how likely they were to recommend each treatment 
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identified in Round 1 using a 7-point Likert scale (1 = Very 
Unlikely to 7 = Very Likely). Pharmacists were also asked two 
items pertaining to tailoring their recommendations, specifically, 
whether they were likely to recommend based on adolescent age 
and adolescent smoking history. 
Round 3: In Round 3, each participant who completed Round 
2 was provided a personalized survey link which contained his/
her response alongside the group median and mode from the 
previous round for each recommendation. Because the objective 
was to determine group consensus, participants were asked to 
retain or alter their recommendations and encouraged to provide 
commentary as warranted. 
Medians and interquartile ranges (IQR) were calculated to 
determine consensus. Consensus to recommend was established 
for recommendations which received an IQR of 1 and median 
rating of at least 6 (Likely to recommend). Qualitative responses 
were coded independently by two authors. Any discrepancies 
were discussed, with all final codes agreed upon by both coders. 
A final question was added to Round 3 based on Round 2 
responses. All pharmacists were asked “Is there a particular 
Smoking Cessation Program you would recommend?” in order to 
identify pharmacist awareness of available programs.
RESULTS AND DISCUSSION
Sample characteristics
Of the 50 pharmacists invited to participate, 40 (80% of 
invited) completed Round 1, 37 (92.5% of invited) completed 
Rounds 2, and 37 (100% of invited) completed Round 3. The 
majority of participants were male (n=23, 62.2%) and White 
(n=31, 83.8%), while some identified as African American (n=4, 
10.8%), American Indian (n=1, 2.7%), or Asian (n=1, 2.7%). 
Participants resided in 14 states: Alabama (n=2), Arizona (n=18), 
Florida (n=2), Idaho (n=1), Illinois (n=1), Iowa (n=1), Kentucky 
(n=3), Kansas (n=1), Michigan (n=1), Ohio (n=1), Pennsylvania 
(n=2), Tennessee (n=1), Texas (n=1), Utah (n=1), and Washington 
(n=1). Pharmaceutical experience ranged from three to 48 years, 
with on average 19.75 years. Participants worked in both retail 
(56.7%) and hospital (43.2%) pharmacies. Participants were 
asked whether they had been approached by adolescents seeking 
NRT and which products adolescents had requested (if any). Of 
the 37 respondents to complete all three rounds of the study, 
17 (45.9%) responded they had been approached directly by 
an adolescent. Of those, 15 (88.2%) said adolescents requested 
nicotine patches, 14 (82.4%) said nicotine gum, 3 (17.6%) said 
nicotine lozenges, 2 (11.8%) said nicotine inhalers, and 1 (5.9%) 
said e-cigarettes.
Round 1: Forty respondents provided 10 different responses 
for the item “What would you recommend for a teen looking to 
quit smoking?” Thirty-six (90%) of those responses included an 
over-the-counter NRT product (patch, gum, or lozenge). Nicotine 
patch and gum were each listed by 23 (57.5%) pharmacists. 
Nicotine lozenges, counseling, behavioral approaches (e.g. 
identifying triggers and counting strategies), and smoking 
cessation programs were each listed by 3 (7.5%) pharmacists. 
Varenicline, bupropion SR, quitline, and cold turkey were each 
mentioned by 1 (2.5%) pharmacist. Additionally, 5 (12.5%) 
pharmacists stated their recommendation would be tailored for 
age or smoking history. 
Thus, 10 recommendations were identified through Round 
1: nicotine patch, nicotine gum, nicotine lozenge, bupropion SR, 
varenicline, quitline, smoking cessation program, counseling, 
behavioral approaches, and cold turkey. Smoking cessation 
program refers to a structured quitting program, typically in a 
group setting, while counseling refers to individualized guidance, 
either formal or not. Behavioral approaches refer to strategies 
such as chewing on a peppermint stick or counting to ten. 
Round 2: Thirty-seven pharmacists completed Round 2. 
Pharmacists were very likely to recommend smoking cessation 
programs (median=7 of 7, IQR=1), likely to recommend behavioral 
approaches (median=6, IQR=2), counseling (median=6, IQR=2), 
quitline (median=6, IQR=3), and nicotine patch (median=6, 
IQR=3); somewhat likely to recommend nicotine gum (median=5, 
IQR=2) and nicotine lozenge (median=5, IQR=3), and somewhat 
unlikely to recommend varenicline (median=3, IQR=3), 
bupropion SR (median=3, IQR=3), and cold turkey (median=3, 
IQR=4). Pharmacists were likely to base recommendations on 
age (median=6, IQR=1) and smoking level (median=6, IQR=1) of 
adolescent. 
Round 3: Of the 10 recommendations identified in Round 1, 
only smoking cessation program met the predetermined criteria 
for consensus to recommend, with an IQR of 1, and median score 
greater than 5. Of 37 respondents, 30 (81.1%) were likely or very 
likely to recommend a smoking cessation program. Remaining 
recommendations are in Table 1. The only other item which 
reached consensus was nicotine gum (median=5, IQR=1), which 
pharmacists were somewhat likely to recommend. Pharmacists 
were likely to recommend behavioral approaches (median=6, 
IQR=2), counseling (median=6, IQR=2), quitline (median=6, 
IQR=3), and nicotine patch (median=6, IQR=3); somewhat 
likely to recommend nicotine lozenge (median=5, IQR=2), and 
somewhat unlikely to recommend varenicline (median=3, 
IQR=2), bupropion SR (median=3, IQR=3), and cold turkey 
(median=3, IQR=4). There were 26 (7.0%) response changes 
between rounds 2 and 3; however, median response scores did 
not change between rounds. 
Based on the increased preference in Round 2 for 
recommending smoking cessation programs, pharmacists in 
Round 3 were asked to list a smoking cessation program they 
would recommend. Of the 37 respondents, nine responded, and 
only one listed a smoking cessation program. Other pharmacists 
responded with cold turkey or quitline which were both other 
recommendations and not smoking cessation programs. 
Qualitative responses
Participants were given space to provide justifications for 
their responses in each round. Participants were not required 
to provide comments, but 40% of pharmacists provided a 
comment on at least one recommendation (Table 2). Pharmacists 
provided several common reasons for their recommendations 
including product effectiveness (n=13), cost (n=7), relevance for 
adolescents (n=7), accessibility (n=6), and concerns about side 
effects (n=15). The qualitative responses provided insight into 
some participants’ recommendations. For example, varenicline 
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Unlikely (3) Undecided (4)
Somewhat 
Likely (5) Likely (6)
Very Likely 
(7)
Nicotine Patch R2 2 5 2 2 5 17 4
R3 2 4 3 1 7 16 4
Nicotine Gum R2 3 3 2 1 11 10 7
R3 2 3 2 0 13 12 5
Nicotine Lozenge R2 3 4 3 5 12 8 2
R3 3 4 4 5 13 7 1
Bupropion SR R2 4 9 7 3 10 3 1
R3 4 8 8 3 11 2 1
Varenicline R2 8 9 5 4 3 5 3
R3 8 10 7 4 3 2 3
Cold Turkey R2 9 6 6 4 6 3 3
R3 9 6 7 4 5 3 3
Quitline R2 0 2 3 5 6 6 15
R3 0 2 3 4 6 8 14
Counseling R2 1 1 4 2 6 9 14




R2 0 0 4 1 3 7 22
R3 0 0 3 1 3 8 22
Behavioral 
Approach
R2 1 0 2 2 5 10 17
R3 1 0 2 1 6 10 17
Abbreviations: Bold print indicates change between R2 and R3. R2: Round 2; R3: Round 3
Table 2: Qualitative themes by product.
Product Number of  Commenters Comments per Code
Nicotine Patch 19
5 said effective, 3 said their responses were similar to group response, 
3 based on personal experience, 3 said safe, 3 said not the best option, 2 were positive but 
vague, 2 said easy to use, 2 said not relevant for adolescents, 1 was concerned about side effects, 
1 said accessible, 1 said inexpensive
Nicotine Gum 19
3 said not the best option, 3 said their responses were similar to group response, 3 said good for 
oral substitution, 3 were positive but vague, 2 based on personal experience, 2 said easy to use, 
1 said safe, 1 said effective, 1 said not effective, 1 said relevant for adolescents, 1 said accessible, 
1 said abuse potential  
Nicotine Lozenge 10
2 said not the best option, 2 said good for oral substitution, 1 was positive but vague, 1 said their 
response was similar to group response, 1 said not effective, 1 said lack of knowledge, 1 said 
stigma, 1 said abuse potential 
Bupropion SR 13
6 were concerned about side effects, 2 said not the best option, 2 said their responses were 
similar to group response, 2 based on personal experience, 1 was positive but vague, 1 was 
negative but vague, 1 said expensive, 1 said not accessible   
Varenicline 13
8 were concerned about side effects, 2 said not the best option, 2 said their responses were 
similar to group response, 1 based on personal experience, 1 was negative but vague, 1 said 
expensive, 1 said not accessible  
Cold Turkey 11 3 said not effective, 2 were positive but vague, 2 were negative but vague, 1 said not the best option, 1 said safe, 1 said lack of knowledge, 1 said relevant for adolescents 
Quitline 13 5 were positive but vague, 3 said not the best option, 2 said inexpensive, 1 said safe, 1 said lack of knowledge, 1 said accessible, 1 said confidential





3 were positive but vague, 2 based on personal experience, 1 said their response was similar to 
group response, 1 said safe, 1 said effective, 1 said easy to use, 1 said lack of knowledge, 1 said 
relevant for adolescents, 1 said stigma 
Behavioral 
Approaches 7
3 were positive but vague, 1 said their response was similar to group response, 1 said safe, 1 
said effective, 1 said relevant for adolescents, 1 said inexpensive  
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and cold turkey received the greatest number of very unlikely 
to recommend scores. The comments for varenicline indicate 
pharmacists were concerned about the side effects. However, 
reasons for recommending or not recommending cold turkey 
were less clear.
CONCLUSION
The purpose of this study was to reach consensus on 
recommendations for adolescent smoking cessation among 
pharmacists. Through a three-round Delphi study, pharmacists 
stated and rated their most likely recommendations for 
adolescents looking to quit smoking. In the final round, 
only smoking cessation program reached consensus for 
recommending. 
In Round 1, pharmacists were overwhelmingly in favor of 
NRT options, with only 25% mentioning anything behaviorally 
related. However, in Round 2 and Round 3, pharmacists 
were between somewhat unlikely and somewhat likely to 
recommended the over-the-counter NRT options, and most 
likely to recommend behavioral options. There are several likely 
explanations for this: (1) pharmacists may have felt limited to 
answers only about medications; (2) pharmacists may have only 
been approached about medication options for cessation and 
therefore more likely to recommend, or (3) pharmacists may not 
be aware of tobacco cessation resources within their community. 
As indicated in the screening survey results, pharmacists were 
most likely approached for NRT products, which may have 
influenced their recommendations. Additionally, as evidenced 
by only one person listing a smoking cessation program, while 
the pharmacists responded as likely to recommend the smoking 
cessation program, it is possible they are not aware of programs, 
which may have influenced their initial response, and also limits 
the usability.
In the USA, NRT is currently restricted to use among those 
18 years of age or older. As the pharmacists in this study were 
directed to respond based on likelihood of recommending 
for those under 18, some may have been concerned with the 
legality of such recommendations. However, none referenced 
legal restrictions as a reason for recommending or not 
recommending any treatments. Nevertheless, it is possible 
current regulations which require prescription for use under 18 
influenced some pharmacists’ recommendations. Additionally, 
the recommendations identified by this sample of pharmacists 
are consistent with current Clinical Practice Guideline [3], though 
none referenced that as a reason for selecting any treatment. 
There were notable cessation treatment options that were not 
recommended within Round 1, and subsequently not discussed 
within this survey, including the nicotine inhaler, nicotine nasal 
spray, and e-cigarettes. The nicotine inhaler and e-cigarettes 
were items for which adolescents had previously approached the 
pharmacists within this sample, however, they were not listed 
as recommendations by pharmacists in Round 1, and, therefore, 
not included throughout the survey. The nicotine inhaler and 
nicotine nasal spray are less prevalent among adults, and, 
therefore, may be less familiar to pharmacists. The nicotine nasal 
spray was found ineffective among one sample of adolescents 
[24], but no studies have looked at use of nicotine inhaler. Despite 
being the most commonly used tobacco product within the USA 
among adolescents, e-cigarettes are not considered a cessation 
treatment within the USA [25], which may be why pharmacists 
did not recommend it as such. However, there is some evidence 
young people may use electronic cigarettes for cessation (26), 
and, therefore, this should be considered within future studies. 
This study contained a number of strengths, as well as 
limitations. There were high response rates between Rounds 
1 and 3, with all respondents from Round 2 completing 
Round 3. Another strength is the abundance of qualitative 
feedback. Nearly half of participants voluntarily submitted 
qualitative feedback which provided insight into responses. 
The first limitation pertains to generalizability. The number of 
pharmacists was necessarily limited, and, as such, the findings 
may not be generalizable. Additionally, each of the participants 
had experience with adolescent substance use, which may not 
represent all pharmacists. Second, we failed to operationalize the 
term ‘cold turkey’. Recent literature indicates the use of the term 
varies. For example, a 2016 study cites ‘cold turkey’ as the best 
approach for smoking cessation [27]. However, this usage of the 
term does not refer to completely quitting smoking without any 
assistance (as was intended by the authors of the current study). 
Instead refers to choosing a quit date and stopping smoking 
completely as opposed to tapering down, while using NRT or 
behavioral treatment. Therefore, future research should clarify 
individual interpretations of ‘cold turkey’. 
Despite these limitations, this study identified pharmacist 
recommendations for adolescent smoking cessation. Results 
indicate pharmacists favored behavioral treatments over 
pharmacological interventions in this patient population, which 
is in agreement with current clinical practice guideline (3). 
However, as indicated in this study, pharmacists may not be 
familiar with specific behavioral treatments. Such preferences and 
knowledge among pharmacists could influence the accessibility 
of treatment to adolescent smokers. Future research should 
address the possibility of pharmacy-based services for tobacco 
cessation, including continuing education for pharmacists 
on adolescent tobacco cessation resources. In studies among 
adults, pharmacists [28], and patients [29], reported interest in 
pharmacy-based cessation. Additionally, qualitative feedbacks 
from pharmacists within this sample indicate an interest in 
helping youth quit smoking.
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